Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study.
Fostira F, Tsitlaidou M, Papadimitriou C, Pertesi M, Timotheadou E, Stavropoulou AV, Glentis S, Bournakis E, Bobos M, Pectasides D, Papakostas P, Pentheroudakis G, Gogas H, Skarlos P, Samantas E, Bafaloukos D, Kosmidis PA, Koutras A, Yannoukakos D, Konstantopoulou I, Fountzilas G. Fostira F, et al. Among authors: bournakis e. Breast Cancer Res Treat. 2012 Jul;134(1):353-62. doi: 10.1007/s10549-012-2021-9. Epub 2012 Mar 21. Breast Cancer Res Treat. 2012. PMID: 22434525
Developments in the systemic treatment of endometrial cancer.
Mountzios G, Pectasides D, Bournakis E, Pectasides E, Bozas G, Dimopoulos MA, Papadimitriou CA. Mountzios G, et al. Among authors: bournakis e. Crit Rev Oncol Hematol. 2011 Sep;79(3):278-92. doi: 10.1016/j.critrevonc.2010.07.013. Epub 2010 Sep 15. Crit Rev Oncol Hematol. 2011. PMID: 20833559 Review.
Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer.
Mountzios I, Bournakis E, Efstathiou E, Varkaris A, Wen S, Chrisofos M, Deliveliotis C, Alamanis C, Anastasiou I, Constantinides C, Karadimou A, Tsiatas M, Papadimitriou C, Bamias A, Dimopoulos MA. Mountzios I, et al. Among authors: bournakis e. Urology. 2011 Mar;77(3):682-7. doi: 10.1016/j.urology.2010.08.044. Epub 2011 Jan 22. Urology. 2011. PMID: 21256546
Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study.
Pentheroudakis G, Batistatou A, Kalogeras KT, Kronenwett R, Wirtz RM, Bournakis E, Eleftheraki AG, Pectasides D, Bobos M, Papaspirou I, Kamina S, Gogas H, Koutras AK, Pavlidis N, Fountzilas G. Pentheroudakis G, et al. Among authors: bournakis e. Breast Cancer Res Treat. 2011 May;127(1):179-93. doi: 10.1007/s10549-011-1427-0. Epub 2011 Mar 9. Breast Cancer Res Treat. 2011. PMID: 21390496 Free article.
Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab.
Koutras AK, Antonacopoulou AG, Eleftheraki AG, Dimitrakopoulos FI, Koumarianou A, Varthalitis I, Fostira F, Sgouros J, Briasoulis E, Bournakis E, Bafaloukos D, Bompolaki I, Galani E, Kalogeras KT, Pectasides D, Fountzilas G, Kalofonos HP. Koutras AK, et al. Among authors: bournakis e. Pharmacogenomics J. 2012 Dec;12(6):468-75. doi: 10.1038/tpj.2011.37. Epub 2011 Aug 16. Pharmacogenomics J. 2012. PMID: 21844885 Clinical Trial.
Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) study.
Pectasides D, Papaxoinis G, Kotoula V, Fountzilas H, Korantzis I, Koutras A, Dimopoulos AM, Papakostas P, Aravantinos G, Varthalitis I, Kosmidis P, Skarlos D, Bournakis E, Bafaloukos D, Kalofonos HP, Kalogeras KT, Fountzilas G. Pectasides D, et al. Among authors: bournakis e. Oncol Rep. 2012 Jan;27(1):216-24. doi: 10.3892/or.2011.1504. Epub 2011 Oct 13. Oncol Rep. 2012. PMID: 22025320 Clinical Trial.
Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study.
Psyrri A, Kalogeras KT, Kronenwett R, Wirtz RM, Batistatou A, Bournakis E, Timotheadou E, Gogas H, Aravantinos G, Christodoulou C, Makatsoris T, Linardou H, Pectasides D, Pavlidis N, Economopoulos T, Fountzilas G. Psyrri A, et al. Among authors: bournakis e. Ann Oncol. 2012 Jun;23(6):1422-7. doi: 10.1093/annonc/mdr527. Epub 2011 Nov 4. Ann Oncol. 2012. PMID: 22056852 Free article.
Heat shock protein 90 (hsp90) expression and breast cancer.
Zagouri F, Bournakis E, Koutsoukos K, Papadimitriou CA. Zagouri F, et al. Among authors: bournakis e. Pharmaceuticals (Basel). 2012 Sep 12;5(9):1008-20. doi: 10.3390/ph5091008. Pharmaceuticals (Basel). 2012. PMID: 24280702 Free PMC article.
35 results